Cyst induction and growth in ADPKD
- Institution
- CINCINNATI CHILDRENS HOSP MED CTR, OH
- Principal investigator
- Cristina Cebrian Ligero
- Funding
- $491K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
Abstract: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the world’s most common life-threatening genetic diseases. Mutations in the genes PKD1 and PKD2 account for 85% and 15% of all ADPKD cases, respectively. ADPKD patients are heterozygous for either PKD1 or PKD2 deleterious mutations; homozygous mutations are considered incompatible with life. Interestingly, loss-of-heterozygosity studies and genome sequencing of patients’ cysts, have documented the clonal nature of the epithelial cysts in ADPKD. Altogether, these data support the two-hit model in which one mutation in either PKD1 or PKD2 is inherited, but a second (somatic) mutation is required for the clonal expansion of the epithelial cells and progression of cystic disease. While these data strongly support the two-hit model, there is scarce data reporting if, when, and how, a second mutation in an individual renal cell affects the behavior of that cell and its environment in vivo. We have generated a series of mouse lines that recapitulates the two-hit model. In an otherwise Pkd2 heterozygous animal, we can induce a second mutation during embryonic development but also at later timepoints. Our data confirms that single mutant cells are responsible for the generation of cysts and that all cells in the cyst arise from the originally mutated cell. Most importantly, our data reveals that not all mutant cells become cysts. We hypothesize that cyst inception is modulated by additional intrinsic and extrinsic factors affecting mutant cells. Specifically, we hypothesize that cyst inception and/or growth is driven by tubular identity, external sources of proliferation and the microenvironment created by the chimeric nature of the disease. We will test these hypotheses in three aims employing mouse models as well as kidney explants and iPSC-derived kidney organoids.
LOADING MOONBASE SCORE
Questions for CINCINNATI CHILDRENS HOSP MED CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same researchers, same institution, same topic, scored first.
- NIH · Cincinnati Childrens Hosp Med CtrNot yet scored
Role of Etv4 and Etv5 in the self-renewal and differentiation of nephron progenitors
Cristina Cebrian Ligero · $445K · 2023–2028
- NIH · Cincinnati Childrens Hosp Med Ctr54
Sirolimus TSC Epilepsy Prevention Study (STEPS) IND#145820 11/8/2019
Martina Bebin · $651K · 2021–2027
- NIH · Cincinnati Childrens Hosp Med Ctr48
Abatacept for the treatment of Common Variable Immunodeficiency with Interstitial Lung Disease (ABCVILD) IND #152820 9/2/20
Michael Jordan · $530K · 2021–2027